Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 2Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Gynecologic 2Sarcoma 1Gastrointestinal 1Breast 1

Conditions

Prostatic Neoplasms 2Prostate Adenocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 44Specimen Handling 38enzalutamide 30Nivolumab 30pembrolizumab 28Docetaxel 23Gemcitabine 22apalutamide 20Prednisone 20Biopsy 20Abiraterone Acetate 18Androgen Antagonists 17cabozantinib 14darolutamide 13abiraterone 13Radiotherapy 13Cisplatin 12enfortumab vedotin 11Radiation 11Ipilimumab 11Pluvicto 10erdafitinib 9belzutifan 9atezolizumab 9X-Rays 9Radiosurgery 9Mitomycin 9olaparib 8cabazitaxel 8Standard of Care 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Radiation Dose Hypofractionation × Genitourinary × 30 days × Clear all
NCT03570827 2026-05-26

Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy

Mayo Clinic

Phase 2 Completed
53 enrolled 11 charts
Genitourinary

Prostatic Neoplasms

NCT03274687 2026-05-20

Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer

NRG Oncology

Phase 3 Completed
296 enrolled 29 charts
Genitourinary

Prostate Adenocarcinoma

NCT03987386 2026-05-20

Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer

M.D. Anderson Cancer Center

Phase 3 Active not recruiting
186 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡